Crinetics Pharmaceuticals (CRNX) EBITDA Margin (2017 - 2026)
Crinetics Pharmaceuticals' (CRNX) quarterly EBITDA Margin came in at 1307.79% in Q1 2026, up 2955232.0% year-on-year from N/an in Q1 2025, and up 39.72% quarter-over-quarter from 2169.55% in Q4 2025.
Crinetics Pharmaceuticals (CRNX) EBITDA Margin (2017 - 2026) Analysis & Trends
Crinetics Pharmaceuticals' EBITDA Margin history runs 10 years deep, the most recent figure standing at 1307.79% for Q1 2026.
- On a quarterly basis, EBITDA Margin rose 2955232.0% year-over-year to 1307.79% in Q1 2026; TTM through Mar 2026 was 3020.32%, a 4654941.0% increase from a year earlier, with the FY2025 full-year figure at 6714.77%, up 2589870.0% from the prior year.
- EBITDA Margin climbed to 1307.79% in Q1 2026 per CRNX's latest filing, from 2169.55% in the prior quarter.
- Across five years, EBITDA Margin topped out at 1080.39% in Q1 2022 and bottomed at 99710.49% in Q3 2025.
- The 5-year median for EBITDA Margin is 9646.51% (2022), against an average of 16434.89%.
- Across the five-year window, EBITDA Margin sank 1937120 bps in 2025 and soared 2955232 bps in 2026, its largest moves.
- Year by year, EBITDA Margin stood at 6707.48% in 2022, then slumped by 154 bps to 17045.38% in 2023, then slipped by 22 bps to 20747.62% in 2024, then surged by 90 bps to 2169.55% in 2025, then surged by 40 bps to 1307.79% in 2026.
- Per Business Quant, the three latest CRNX EBITDA Margin figures stand at 1307.79% (Q1 2026), 2169.55% (Q4 2025), and 99710.49% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,200.25 Bn | 66,199.96 Bn | - | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.75 Bn | 466.96 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.43 Bn | 62.43 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | 31.68% |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 23.02% |
| 10 | Crinetics Pharmaceuticals | 8.73 Bn | 7.43 Bn | 10.53 Mn | -1,307.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,307.79% |
| Dec 31, 2025 | -2,169.55% |
| Sep 30, 2025 | -99,710.49% |
| Jun 30, 2025 | -12,522.99% |
| Mar 31, 2025 | -30,860.11% |
| Jun 30, 2024 | -20,747.62% |
| Mar 31, 2024 | -11,488.91% |
| Sep 30, 2023 | -17,045.38% |
| Jun 30, 2023 | -5,363.87% |
| Mar 31, 2023 | -1,790.89% |
| Dec 31, 2022 | -6,707.48% |
| Sep 30, 2022 | -9,487.77% |
| Jun 30, 2022 | -9,805.24% |
| Mar 31, 2022 | -1,080.39% |
| Dec 31, 2021 | -2,865.31% |
| Dec 31, 2020 | 30,691.55% |
| Mar 31, 2020 | -25,045.07% |
| Dec 31, 2019 | -4,739.56% |
| Sep 30, 2019 | -3,015.64% |
| Mar 31, 2019 | -2,736.78% |